GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CKD Bio 063160.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

11,290

0.00%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CKD Bio

Its shares trade on KRX under the ticker 063160.KS. It has been listed since 11 December 2001. In the fiscal year to 31 December 2025, it reported revenue of ₩160.07bn and a net loss of ₩2.89bn. At that date it held total assets of ₩299.87bn and shareholders' equity of ₩127.04bn.

CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-12-11. The firm mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. The company also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The firm distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
11 Dec 2001
Website
ckdbio.com ↗

Leadership

Pay as last reported

  • Joeng Jin LeeChief Executive Officer, Director, since 2017
  • Saeng Gyu SeoAssistant Managing Director, since 2012
  • Hak Yeon HwangAssistant Managing Director
  • Hae Mun LeeInternal Auditor
  • Gwang Seop GilNon-Executive Independent Director
  • Hae Hun YoonIR Contact Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • CKD Bio Corp develops DMCTs and rifampicins for antibiotic ingredients in the Korean market.
  • The company provides cyclosporin and tacrolimus as immunosuppressive agents globally.
  • CKD Bio Corp distributes acarbose for diabetes and potassium clavulanate to multiple regions.

Weaknesses

  • CKD Bio Corp relies on domestic market for antibiotic ingredients like DMCTs and rifampicins.
  • The firm's immunosuppressive agents face competition in global markets.
  • Limited product range for diabetes remedies beyond acarbose in the Korean market.

Opportunities

  • Expanding antibiotic ingredient exports to Southeast Asia and Africa markets.
  • Increasing demand for immunosuppressive agents in Europe and America.
  • Growing market for diabetes remedies like acarbose in Latin America.

Threats

  • Competition from other pharmaceutical firms in the Korean market.
  • Regulatory changes affecting antibiotic ingredient exports to Europe.
  • Economic instability in Southeast Asia impacting pharmaceutical distribution.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.